Bushen Huoxue Prescription Regulates PINP and β-CTX in Treatment of Femoral Head Necrosis with Syndrome of Liver and Kidney Deficiency
10.13422/j.cnki.syfjx.20240896
- VernacularTitle:补肾活血方治疗股骨头坏死肝肾亏虚证的临床疗效及对骨代谢指标PINP、β-CTX的影响
- Author:
Zijia LIU
1
;
Ying LI
1
;
Pengtao CUI
2
;
Bowen WANG
3
;
Peigang ZHANG
3
;
Wuyue TONG
3
;
Zhihui ZHANG
3
;
Yuju CAO
2
Author Information
1. Nanyang Second General Hospital，Nanyang 473000，China
2. Zhengzhou Traditional Chinese Medicine Hospital of Orthopedics，Zhengzhou 450016，China
3. College of Orthopedics and Traumatology，Henan University of Chinese Medicine，Zhengzhou 450002， China
- Publication Type:Journal Article
- Keywords:
Bushen Huoxue prescription;
osteonecrosis of femoral head;
syndrome of liver and kidney deficiency;
bone metabolism;
Youguiwan
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2024;30(3):81-89
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo explore the therapeutic mechanism of Bushen Huoxue prescription from the perspective of bone metabolism by observing the clinical efficacy of this prescription in treating femoral head necrosis （ONFH， syndrome of liver and kidney deficiency） and its influences on bone metabolism indexes： N-terminal propeptide （PINP） and β-collagen degradation product （β-CTX）. MethodSixty-six ONFH patients with the syndrome of liver and kidney deficiency in Zhengzhou Traditional Chinese Medicine Hospital of Orthopedics from December 2021 to September 2022 were selected. The patients were randomized into an experimental group and a control group by the parallel control method， with 33 patients in each group. The experimental group received Bushen Huoxue prescription orally， while the control group received Xianlinggubao Capsules orally， with a treatment cycle of 6 months. The visual analogue scale （VAS） score， Harris score， Association Research Circulation Osseous （ARCO） staging， imaging changes， quantitative scores of TCM symptoms， and serum levels of PINP and β-CTX were determined before and after treatment. The occurrence of adverse events and reactions was recorded. ResultThe total response rate in the experimental group was 83.87% （26/31）， which was higher than that （68.75%， 22/32） in the control group （Z=-2.096， P<0.05）. After treatment， the single and total scores of TCM symptoms， VAS score， and β-CTX level decreased in the two groups （P<0.05）. Moreover， the decreases in the scores of hip pain， lower limb mobility， soreness of waist and knees， and lower limb flaccidity， total score of TCM symptoms， VAS score， and β-CTX level in the experimental were larger than those in the control group （P<0.05）. After treatment， the imaging results showed no significant improvement in the two groups. The Harris score and PINP level in both groups increased after treatment （P<0.05）， and the increases were more obvious in the experimental group than in the control group （P<0.05）. No serious adverse event or adverse reaction appeared during the observation period. ConclusionBushen Huoxue prescription can relieve pain and TCM symptoms and improve the hip joint function in treating ONFH patients with the syndrome of liver and kidney deficiency. It can inhibit the development of ONFH， increase PINP， and decrease β-CTX. No obvious side effect appears during the clinical observation period， which shows that Bushen Huoxue prescription has good safety.
